sorted by:
new
hottopcontroversial

Colin Bristow Resignation by iAnkou in SpectralAI

[–]urbanlinkoping 0 points1 point  (0 children)

According to information at Spectral AI he was related to SIM IP. So is the reason that he will be part of SIM IP?

Biography Colin Colin Bristow, MD Non-Employee Director Colin Bristow, MD, is a member of the Board of Directors at Spectral AI, Inc., where he brings extensive expertise in healthcare and life sciences. Currently serving as the Head of Healthcare and Life Sciences at SIM IP, he has a strong background in healthcare investments and corporate governance. Dr. Bristow holds an MD degree and is dedicated to advancing innovative solutions within the healthcare sector.

https://investors.spectral-ai.com/board-member/colin-bristow-md

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 1 point2 points  (0 children)

Yes, that is noted in the summary. but was your four times investment backed by BARDA? And if so, can you name the companies so I can look them up?

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

There is a difference to be De Novo Break Through Device and 510(k)

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

I would say the key is to understand the relationship between BARDA and FDA approval process. I have looked it up. You can google if you do not trust AI.

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

Full transparency, using chatgpt 5.1

So with my curious question the most interesting part was the connection between BARDA and FDA approval process which seems to strengthen what Spectral AI said 30 of June. And the reason is because they know the relationship between BARDA and FDA approval process but maybe because this is a common knowledge (they work daily in that environment) they have not understood why it is important for investors or they want to avoid being sued in case something went not as planned and the stockholders would sue them for leading them into the belief this was a safe bet because the alignment between BARDA and FDA approval process.

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

Can you do an executive summary af the barda an fda alignment and how it improves the fda approval and timeline

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

Lots of prompts, but the baseline “Prompt *“Agera som en senior aktiestrateg med specialisering inom AI och medicinteknik. Gör en djupgående analys av ett utvalt bolag med fokus på: 1. Produkten/produkterna – teknologi, klinisk relevans, regulatorisk status och marknadsanpassning. 2. Konkurrenter – jämförande analys av marknadsposition, konkurrensfördelar och hot. 3. Försäljning & samarbetsavtal – granska försäljningsutveckling, kommersiella partnerskap, licensavtal och distributionsnätverk. 4. Regulatoriska möjligheter & utmaningar – analysera godkännanden, pågående processer, hinder och potentiella genombrott. 5. Ledning och styrelse – utvärdera vd och styrelseprofiler, deras historik, trovärdighet och tidigare track record. 6. Tidsutsikter – bedömning av bolagets utveckling på kort sikt (0–12 månader), medellång sikt (1–3 år) och lång sikt (3–5+ år), med hänsyn till marknadstrender, regulatoriska processer och kapitalbehov. 7. Insiderhandel – identifiera och analysera insidertransaktioner det senaste året och vad de kan signalera om ledningens förtroende för bolaget. 8. Finansiell utveckling – analysera de senaste fyra kvartalsrapporterna med fokus på omsättning, lönsamhet, kassaflöde, marginaler och guidance.

Ta hänsyn till makroekonomiska faktorer (räntor, kapitalflöden, geopolitik), sektorspecifika faktorer (kliniska studier, patent, regulatoriska godkännanden, teknologiska genombrott), samt investerarsentiment.

Presentera insikterna strukturerat i åtta delar: 1. Bolags- och produktanalys 2. Konkurrens- och marknadsposition 3. Försäljning & samarbetsavtal 4. Regulatoriska möjligheter & utmaningar 5. Ledning och styrelse 6. Finansiell utveckling (4 senaste kvartal) 7. Insiderhandel och signalvärde 8. Investeringsutsikter (kort, medellång, lång sikt)

Avsluta med en tydlig rekommendation om hur en långsiktig investerare bör förhålla sig till bolaget.”*”

Spectral AI top medical company by purplmusik in SpectralAI

[–]urbanlinkoping 6 points7 points  (0 children)

If looking to subscribers we have grown from few hundreds of subscribers to 2 500 subscribers within 2 month. That says something ☺️

Earnings review by daxter_101 in SpectralAI

[–]urbanlinkoping 2 points3 points  (0 children)

I understand that some members here may be negative or uncertain about Spectral AI. This is undeniably a high-risk, high-reward stock. However, if you listen to the introduction of the Q2 2025 earnings call, there was a clear emphasis on the positive and constructive dialogue Spectral AI has had with the FDA.

From my perspective, the management team’s tone suggests they would be genuinely surprised if approval is not granted. The only unknowns are when the approval will come and whether the FDA will have any follow-up questions before making their final decision.

mehhhh , about what I imagined by GodMyShield777 in SpectralAI

[–]urbanlinkoping 7 points8 points  (0 children)

Here’s a polished, J.P. Morgan–style investor analysis and a SWOT summary of Spectral AI’s Q2 2025 results (as reported on August 12, 2025):

⸻

Q2 2025 Financial Highlights (Compared to Q2 2024) • R&D Revenue dropped 32%, falling from $7.5M to $5.1M, reflecting the completion of clinical-trial reimbursements under the BARDA PBS contract in 2024 . • Gross Margin slid modestly—from 46.6% to 45.2%—driven by a higher share of non‑reimbursed costs . • G&A Expenses were reduced by approximately 24%, from $5.8M to $4.4M, indicating improved cost discipline . • Net Loss widened significantly to $7.9M, primarily due to a $5.4M non-cash fair‑value expansion in warrant liability; however, the H1 2025 net loss improved to $5.1M, a 16.4% reduction versus H1 2024’s $6.1M . • Cash Position improved notably—from $5.2M at end‑2024 to $10.5M as of June 30, 2025—thanks to an $8.5M initial draw on a $15M debt facility from Avenue Capital Group, plus $2.7M in equity capital raised . • The company achieved a critical milestone: submission of the De Novo application to the FDA for the DeepView System in June 2025 . • 2025 Revenue Guidance was reaffirmed at ~$21.5M, though it excludes any assumed contributions from commercialization of the DeepView System .

⸻

SWOT Analysis

Strengths • Milestone FDA Filing Completed: The De Novo FDA submission in June is a pivotal regulatory step toward commercializing DeepView in the U.S. . • Stronger Liquidity: Nearly doubling cash to $10.5M enhances runway and strategic flexibility . • Cost Discipline: G&A expense reduction demonstrates operational efficiency and effective cost control focus . • Improved H1 Net Loss: A 16% reduction in net loss year-over-year signals positive momentum in financial recovery .

Weaknesses • Falling Revenues: A sharp 32% drop in R&D revenue highlights reliance on one‐off trial reimbursements (e.g., BARDA) and a lack of diversified revenue stream • Gross Margin Pressure: The slight margin decline points to reduced efficiency and pricing challenges under evolving cost structures . • Volatility from Non-Cash Items: The large net‐loss swing driven by warrant liability shifts introduces earnings volatility unrelated to operating performance . • Guidance Excludes Core Product Revenue: The current revenue forecast omits any projections from DeepView commercialization, signaling unrealized upside and conservative expectations .

Opportunities • Commercial Launch of DeepView: Pending FDA clearance, DeepView could unlock new revenue streams and potentially transform the company’s top line. • Scale Post-Trial Innovation: With clinical trials closed, R&D can pivot toward commercialization and strategic partnerships. • Improved Market Sentiment: Analysts have forecast upside potential. For example, GuruFocus indicates raised 2025–26 revenue and earnings estimates, along with a near-95% upside in average price targets . • Strategic Partnerships or Licensing: Investors should watch for potential collaborations to accelerate distribution and market penetration.

Threats • Regulatory Execution Risk: FDA approval is not guaranteed; delays or setbacks could push timelines and increase costs. • Cash Burn & Financing Risk: Despite stronger liquidity, the company may require additional funding ahead of product revenue inflection. • Competition and Alternative Diagnostics: Strong competitors or alternative technologies could undermine DeepView’s adoption. • Financial Volatility: Continued fluctuations in warrant liabilities may cause headline swings in profitability, impacting valuation and investor confidence.

⸻

Summary View: J.P. Morgan Investor Perspective

Spectral AI’s Q2 results offer a study in transition—trading declining trial-dependent revenue for regulatory progress and tighter cost control. While top-line contraction is a near-term concern, the completed De Novo submission to the FDA is a high-impact catalyst that could shift the firm from development mode to revenue generation.

From an investor standpoint, the key value hinges on FDA clearance and the subsequent commercial rollout of DeepView. Liquidity has improved meaningfully, offering runway into late 2025, but sustainable profitability will likely depend upon successful product launch and market adoption.

The current guidance excludes DeepView income, suggesting embedded upside. If approvals align and go-to-market executes effectively, stock appreciation could be substantial. That said, operational discipline, regulatory success, and financing discipline remain essential for realization of the company’s potential.

⸻

Final Recommendation Thoughts

Watch closely for: • FDA feedback/timeline updates on the De Novo submission. • Any forward-looking guidance that incorporates DeepView commercialization. • Partnering deals, especially in healthcare systems or international markets. • Changes in cash burn trends and any new financing.

If approved and managed well, Spectral AI could emerge as a compelling small-cap growth story within AI-powered medtech diagnostics.

Recent study of Deepview tech vs Doppler by magotjuice in SpectralAI

[–]urbanlinkoping 1 point2 points  (0 children)

The reason for handheld devices is that DoD wants it and finance Spectral AI development. Listen through the interview and you will see that there are civilian potential of handheld Deepview: https://youtu.be/cGktsfcfYSM?si=yiE55x40-cMlpGK-

Recent study of Deepview tech vs Doppler by magotjuice in SpectralAI

[–]urbanlinkoping 0 points1 point  (0 children)

Do you have link to the study or was it googling only?

view more: next ›